The demand for oncology services in the United States (US) is increasing, whereas a shortage of oncologists looms.
Decision making for treatment of localized prostate cancer is often guided by therapeutic side-effect profiles. The authors sought to assess health-related quality-of-life outcomes for patients 48 months after treatment for localized prostate cancer. Men treated for localized prostate cancer were evaluated before treatment and at 11 intervals during the 48 months after intervention. Changes in mean health-related quality-of-life scores and the probability of regaining baseline levels of health-related quality of life were compared between treatment groups.
Economic evaluations of health care can be used by policy makers and other decision makers to compare the cost effectiveness of different treatment strategies and to make decisions about the allocation of scarce resources, such as dollars spent on health care.
The authors identified substantial disparities in continent urinary diversion which, based on yearly trends, are unlikely to improve in the near future.
The authors assessed the impact of bother with urinary and bowel dysfunction on social activities among men in Japan and the United States following primary therapy for localized prostate cancer.
Unlike other malignancies, there is no literature supporting the accuracy of medical claims data for identifying surgical treatments among patients with kidney cancer. The authors sought to validate externally a previously published Medicare-claims-based algorithm for classifying surgical treatments among patients with early-stage kidney cancer.
Evaluates the relationship of sex and race with the receipt of timely and clinically appropriate non-small-cell lung cancer (NSCLC) treatment for each stage of diagnosis using Surveillance Epidemiology and End Result data linked to Medicare claims for beneficiaries diagnosed with NSCLC between 1995 and 1999 while controlling for other demographic characteristics, comorbidities, socioeconomic status, and provider supply.
Studies how symptoms for women with incident breast cancer are addressed by physicians and how management varies with patient characteristics. Black and Spanish-speaking Hispanic women were significantly more likely to report an unmet need.
This study examines the burden of symptoms by treatment type and patient characteristics in a population-based sample of newly diagnosed breast cancer patients.
The authors surveyed cancer physicians to understand how patients' age and comorbidity influence adjuvant chemotherapy recommendations and whether physician or practice characteristics also affect these recommendations.
Examines progress in supportive cancer care, which encompasses direct and treatment-related impacts of cancer, including management of pain and other symptoms, and the psychosocial context, including spirituality and challenges of caregiving.
Identifies symptom clusters that include urinary and erectile dysfunction among men treated for prostate cancer. Fatigue and emotional distress may be seen together or in combination with prostate cancer-specific symptoms.
Most men diagnosed with prostate cancer will die of other causes. Accurate stratification by risk of other cause mortality may reduce needless treatment. Future studies should consider stratifying patients by or at least reporting these variables.
Social disparities in breast cancer outcomes may be in part the result of lower quality chemotherapy doses in the adjuvant treatment of breast cancer.
Kidney cancer, the third most common urologic malignancy and the seventh most common cancer overall, was diagnosed in an estimated 35,000 Americans in 2005, and nearly 13,000 died from it.
Satisfaction with diagnosis and treatment information is greater than satisfaction with survivorship issues
The authors sought to examine the influence of patient-centered care activities on ongoing tamoxifen use 4 years after initiation.
Among the challenges that face physicians who care for men with prostate cancer is evaluating the patient's potential for benefiting from treatment.
Variations in patterns of care and treatment outcomes suggest differences in the quality of care for men treated for localized prostate cancer.